

## **CivicaScript® to distribute low-cost biosimilar to treat chronic inflammatory conditions**

***January launch of ustekinumab-aaaz to CivicaScript customers will expand company's rapidly growing product portfolio***

**LEHI, UTAH, AUGUST 5, 2025** – CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced that it will distribute the biosimilar ustekinumab-aaaz, used for treatment of chronic inflammatory conditions in certain patients with plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.

The product will be available starting Jan. 1, 2026. Ustekinumab-aaaz is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23, which play an important role in inflammatory and immune responses. Specific information about ustekinumab-aaaz can be found [here](#).

The company's expansion into biosimilars builds on the steady growth of its specialty generic product portfolio, with four products launched in 2025. CivicaScript will be the exclusive distributor of unbranded ustekinumab-aaaz, produced by Fresenius Kabi. Ustekinumab-aaaz is interchangeable\* to the reference product Stelara® (ustekinumab) injection for subcutaneous or intravenous use.

CivicaScript will sell ustekinumab-aaaz in prefilled syringes in two different strengths. The Wholesale Acquisition Price (WAC) for a 12-week supply of 90 mg will be \$985 and the WAC for a 12-week supply of 45 mg will be \$575. The biosimilar will be available at this low, transparent price to CivicaScript's members and partners, including health plans and pharmacy benefit managers.

"The launch of ustekinumab-aaaz is a major step forward in our mission to make essential medicines more affordable and accessible to all," said CivicaScript President Brent J. Eberle. "We're proud to offer a biosimilar that leverages our transparent business model to help reduce the financial burden on patients and the healthcare system. We expect this to be the first of several biosimilars we add to our portfolio over the next few years."

### **About CivicaScript**

CivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A not-for-profit, limited liability company, CivicaScript is committed to the principles of providing affordable, essential generic

medicines to promote the social welfare and health of the community. For more information on the organization and our mission, visit [our website](#). CivicaScript is the Civica, Inc. operating unit for outpatient medications to help drive affordability and price transparency.

**About ustekinumab-aaaz**Indications

Ustekinumab-aaaz is an IL-12/23 antagonist indicated for treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; active psoriatic arthritis; moderately to severely active Crohn's disease; moderately to severely active ulcerative colitis. Ustekinumab-aaaz is also indicated for pediatric patients ≥6 years of age with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and active psoriatic arthritis.

Contraindications

Ustekinumab-aaaz is contraindicated in patients with clinically significant hypersensitivity to ustekinumab products or to any of the excipients in ustekinumab-aaaz.

\*For more information, please see [Prescribing Information](#).

**MEDIA CONTACT:**

Liz Power

[liz.power@civicarx.org](mailto:liz.power@civicarx.org)

+1 860 501 3849